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Abstract: In this work we studied the functional differences between the microcirculation of murine tumours 
that express only single isoforms of vascular endothelial growth factor-A (VEGF), namely VEGF120 and 
VEGF188, and the effect of VEGF receptor tyrosine kinase (VEGF-R TK) inhibition on their functional 
response to the vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P), using measurement of red 
blood cell (RBC) velocity by a ‘keyhole’ tracking algorithm. RBC velocities in VEGF188 tumours were 
unaffected by chronic treatment with a VEGF-R tyrosine kinase inhibitor, SU5416, whereas RBC velocities 
in VEGF120 tumours were significantly increased compared to control VEGF120 tumours. This effect was 
accompanied by a reduced tumour vascularisation. Pre-treatment of VEGF120 tumours with SU5416 made 
them much more resistant to CA-4-P treatment, with a RBC velocity response that was very similar to that of 
the more mature vasculature of the VEGF188 tumours. This study shows that vascular normalization 
following anti-angiogenic treatment with a VEGF-R tyrosine kinase inhibitor reduced the response of a 
previously sensitive tumour line to CA-4-P.  
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1. Introduction 
 
 Vascular endothelial growth factor-A (commonly known as VEGF[1]) is the predominant 
protein involved in normal and tumour angiogenesis, a process crucial for the supply of oxygen, 
nutrients and growth factors to tumours [2]. The VEGF gene undergoes alternative splicing to 
produce multiple functional isoforms, such as 121, 165 and 189 in human [3] and 120, 164, and 188 
in the mouse [4]. Fibrosarcoma cell lines have been developed to express single isoforms of VEGF 
and used to study their roles in tumour vascularisation. Tumours expressing only VEGF120 are well 
vascularised, but present with immature blood vessels that are fragile and leaky and the tumours are 
prone to haemorrhage, particularly when grown in the dorsal skin-flap window chamber model, 
where vessels struggle to penetrate beyond the tumour edge [5]. VEGF188 expressing tumours have 
a lower vascular volume than VEGF120 tumours, but the blood vessels are much more mature, 
showing good levels of pericyte coverage and less haemorrhage [5].  
 
Vascular disrupting agents (VDAs) are a group of compounds that selectively target tumour 
vasculature and cause a devastating collapse of blood flow in solid tumours, culminating in tumour 
cell death. It is thought that VDAs preferentially target immature tumour blood vessels, with most 
evidence derived from VDAs that are tubulin-binding and endothelial cytoskeleton disrupting [6]. 
Disodium combretastatin A-4 3-O-phosphate (CA-4-P) is the lead tubulin-binding VDA and studies 
have shown that VEGF120 tumours that present with immature vessels showed reduced vascular 
and growth response to CA-4-P, compared with VEGF188 tumours that possess a more mature 
vascular network [5]. 
- 3 - 
 
The VEGF receptor family of proteins belong to the protein tyrosine kinases that regulate multiple 
cellular processes that contribute to tumour development and progression, including cell 
proliferation, differentiation and cell survival [7, 8], and many human tumours exhibit aberrant 
tyrosine kinase activity that drives their growth.  Tyrosine kinase inhibitors therefore represent 
attractive anti-tumour or anti-vascular targets in the clinic [7, 9]. Several multi-target tyrosine 
kinase inhibitors that include targeting VEGF receptors have reached clinical practice or are in 
clinical trial [10, 11]. Under some dosing strategies, treatment with VEGFR-2 receptor antibodies 
or small molecule inhibitors can result in tumour vascular ‘normalisation’, whereby vascular 
morphology is altered and blood flow is improved over a limited time-frame [12-14]. However, 
very little is known about how chronic tyrosine kinase inhibitors affect the function and 
morphology of the surviving blood vessels in tumours, and how this affects subsequent treatment 
stratagems. We sought to investigate the effects of tyrosine kinase receptor inhibition on the 
development of tumours expressing single isoforms of VEGF, and their subsequent response to CA-
4-P treatment.  
 
2. Methods 
 
All experiments were conducted in accordance with the United Kingdom Home Office Animals 
(Scientific Procedures) Act 1986 and with local ethical approval. CA-4-P was kindly provided by 
Professor GR Pettit, Arizona State University. 
 
2.1 VEGF isoform cell lines and tumours 
 
Development of cell lines is described previously [5], but briefly, primary mouse embryo 
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fibroblasts expressing only single isoforms of VEGF (120, 164 or 188) or all isoforms were isolated 
from 13.5 days post-coitum (dpc) embryos produced by heterozygous breeding pairs of single 
VEGF isoform-expressing mice on a Swiss background. Fibroblast cultures were genotyped, as 
described [15], to identify wild-type samples and those homozygous for the Vegfa120, Vegfa164 or 
Vegfa
188 allele. Fibroblasts were immortalised and oncogenically transformed by retroviral 
transduction with SV40 and HRAS (h-ras) [16, 17]. In this study we used only VEGF120 and 188 
tumours as they present with the widest functional and morphological diversity for comparison.  
 
2.2 Window Chambers  
 
All surgery was carried out on male severe combined immunodeficiency (SCID) mice (12-16 week-
old, 28-32g) under general anaesthesia using intraperitoneal (i.p) injection of fentanyl citrate 
(0.8mg•kg-1) and fluanisone (10mg•kg-1; Hypnorm, Janssen Animal Health) and midazolam 
(5mg•kg-1; Hypnovel, Roche, Welwyn Garden City, UK). Animals were kept warm during surgical 
procedure, and aseptic technique was used throughout. Surgical procedures are similar to those 
described previously [18]. Briefly, animals were shaved, depilated and a 15 mm diameter circular 
area of dorsal skin was removed, as well as the subcutaneous (s.c.) fat and connective tissue of the 
opposing skin layer, leaving the exposed panniculus muscle. An aluminium window chamber (total 
weight ∼2g), designed to hold two parallel glass windows, was implanted onto the dorsal skin. A 
tumour fragment (∼0.5 mm in diameter, either VEGF120 or 188) from a donor animal was 
implanted onto the exposed panniculus muscle and the chamber was closed with a glass window to 
provide a depth of ~200 µm for tumour growth. Sub-cutaneous dextrose saline and intraperitoneal 
buprenorphine (Vetergesic) were used to aid recovery and animals were kept in a warm room, 28-
30 °C, until the day of experiment. Animals were grouped for treatment and received either the 
VEGF-R tyrosine kinase inhibitor, SU5416 (50 mg•kg-1, at a concentration of 25 mg•ml-1 
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subcutaneously) or vehicle control (50 µl of DMSO per mouse) as used previously [19] starting at 
day 3 after implant, and then given every 4th day until further experimentation.  
 
2.3 Red Blood Cell labelling  
 
Donor red blood cells (RBC) were obtained via cardiac puncture from donor male SCID mice and 
labelled with the fluorescent dye 1,1', di-octadecyl-3,3,3'3'tetramethylindocarbocyanine perchlorate 
(DiI) (Molecular Probes, Cambridge Biosciences, UK) for the measurement of RBC velocity in the 
tumour vasculature. The labelling method has been published previously [20], but briefly the RBCs 
were separated from blood plasma and white blood cells by centrifugation and the isolated and 
washed RBCs incubated with DiI for 30 mins. 25 µg of DiI was used per 50 µl of packed RBCs. 
After incubation the RBCs were washed and resuspended in phosphate buffered saline (50 µl•ml-1 
RBC-DiI complex). The labelled cells were kept for 3 days at 4°C.  
 
2.4 Intravital Microscopy  
 
Intravital microscopy permits the observation of RBC movement in microvessels of small animals 
under both normal and pathological conditions [21]. The analysis of RBC velocities is used in many 
areas of research, to measure the responsiveness to vasoactive drugs [22] or response to vascular 
disrupting agents [23]. Approximately 7-11 days after surgery, when control or SU5416 treated 
tumours reached ∼3.0 mm in diameter, mice were given 0.2 ml (i.v.) of the RBC-DiI complex and 
treated with a single dose of the vascular disrupting agent, CA-4-P (30mg•kg-1, iv at a concentration 
of 3 mg•ml-1 in 0.9 % NaCl). Tumours were monitored immediately before and at 24 hrs after 
treatment using a Nikon Eclipse E600FN fluorescence microscope with modified stage, under epi-
fluorescence illumination (100 W mercury arc lamp). Videos were taken for 60s at each time point 
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for analysis of RBC velocity. Fluorescence was set up to excite at 550nm and detect the emissions 
at 565nm from the labelled RBCs using a custom-made fluorescence cube (Nikon, UK). 
 
2.5 Velocity Analysis 
 
RBC velocities were calculated from data recorded using a x20 objective with the same region of 
interest used at each time point. Velocities were calculated using a keyhole tracking algorithm 
performed in Matlab, as described previously [24]. 
 
Briefly, the tracking algorithm consisted of three main steps. Firstly, Pre-processing transformed 
the videos into a sequence of binary images that contained segmented foreground objects (RBCs). 
The number of operations and time required to process was reduced by averaging data from 
contiguous pixels. Intensity inhomogeneity was corrected [25] and artefacts were removed with a 
mean image of the temporal sequence. The centroids of the RBCs were determined together with 
the distances that separated them from neighbours, if any. Secondly, Tracking linked the objects in 
contiguous frames to form the tracks by means of a ‘keyhole model’, which predicted the most 
probable landing position of a ‘child’ RBC at time t+1 from the position of the ‘parent’ at times t-1 
and t. Two regions of probability where the RBC is most likely to land were defined: a narrow 
wedge (60° wide) oriented towards the predicted landing position, and a truncated circle (300°) that 
complements the wedge; together they resemble a keyhole. All segmented RBCs were examined for 
possible parent-child relationships and, where these occurred, they formed a series of tracks of 
different lengths. The third step, Post-processing, removed links in tracks that could have resulted 
from noise, and joined sections that were considered to be split sections from a single track. The 
same keyhole model was used analysing backward movement i.e. the grandchild (t+2) and the child 
(t+1) were used to generate a keyhole at time (t). If the RBC of a previous time point was found to 
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land inside the keyhole, it remained as part of the track, otherwise it was removed. Finally outliers 
were removed: those tracks whose average velocity exceed 3 times the standard deviation from the 
mean average velocity of the whole distribution were discarded.  
 
Velocity was calculated at µm•s-1 from the number of video frames taken for each red cell to travel 
between two points of measured distance. The average was weighted according to the length of 
each track to avoid biasing from small tracks. Fig. 1a shows a sample fluorescence image where the 
bright spots describe RBCs and coloured lines describe the tracks that were detected at that frame 
(the tracks spanned several frames). Fig. 1b shows all the tracks detected for a video sequence, with 
time as the vertical axis, and Fig 1c shows the detected RBCs as white blobs circled in red. This 
process enables rapid and automated calculation of velocity for many red blood cells within a 
particular time-frame. 
 
2.6 Statistics 
 
Statistical analysis was performed using SPSS version 11.0.2 for the Apple Macintosh.  Data are 
presented as mean ± standard error of the mean. Student’s unpaired t-test was used to test for 
significant differences between two groups. Differences were considered significant at P<0.05. 
 
3. Results 
 
As expected, repeat administration of the VEGF-R tyrosine kinase inhibitor, SU5416, during 
tumour growth inhibited vascularisation of both VEGF120 and VEGF188 tumours, as illustrated in 
Fig. 2. SU5416 also significantly increased red blood cell (RBC) velocity in the VEGF120 tumours 
compared with vehicle-treated controls (Fig. 3a). However, there was no significant effect of 
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SU5416 in VEGF188 tumours, where RBC velocity was already high (Fig. 3b). Comparison of 
Figs. 3a and 3b shows that SU5416 pre-treatment increased RBC velocity in the VEGF120 tumours 
to similar levels as in the vehicle pre-treated VEGF188 tumours. Differences in response to CA-4-P 
± SU5416 were also found between the tumour types (Figs. 3a,b). Specifically, without SU5416 
pre-treatment, RBC velocity in VEGF120 tumours was significantly decreased 24h following a 
single dose of CA-4-P, whereas RBC velocity in VEGF188 tumours was unaffected at this time, 
consistent with our previous findings [5]. However, SU5416 pre-treatment significantly reduced the 
effect of CA-4-P in the VEGF120 tumours, with a less than 30% reduction in RBC velocity that 
was not significantly different from the pre-CA-4-P time point (P = 0.25; Fig. 3a). In contrast, 
SU5416 pre-treatment did not affect response to CA-4-P of the already resistant VEGF188 tumours 
(Fig. 3b).  
 
4. Conclusions 
 
Treatment with CA-4-P caused significant reduction in RBC velocity, with no recovery over 24 
hours, in VEGF120 tumours, whereas VEGF188 tumours were much more resistant to the effects, 
in line with previous data [5]. However, pre-treatment with the tyrosine kinase VEGF receptor 
inhibitor, SU5416, modified the vasculature of VEGF120 tumours, such that RBC velocity was 
increased and response to CA-4-P was reduced. SU5416 had little or no effect on RBC velocity of 
VEGF188 tumours or their response to CA-4-P at the studied time points.  
 
These data support the notion that expression of VEGF188 in tumours confers a level of protection 
from the effects of CA-4-P. Previous results have shown that these tumours have a more mature 
stable vasculature, which likely contributes to this protection [5]. The immature blood vessels in 
VEGF120 tumours are rapidly broken down. Tyrosine receptor kinase inhibition with SU5416 
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significantly increased RBC velocity in individual vessels of VEGF120 tumours, which was 
accompanied by decreased vascularisation. SU5416 and similar agents were designed to block 
tumour angiogenesis by interfering with VEGF-mediated effects such as endothelial proliferation 
and migration. However, the current results support existing evidence that a sub-optimal anti-
angiogenic effect can result in a rarefied tumour vascular bed, which nevertheless is efficiently 
perfused and capable of sustaining tumour growth (vascular normalization) [14]. In addition, we 
show that pre-treatment with the tyrosine receptor inhibitor reduced the efficacy of a vascular 
disrupting agent (VDA), which is designed to target the established tumour vasculature. It is 
impossible at this stage to determine what changes have taken place to incur this protection from 
the vascular disrupting effects of CA-4-P. Further studies are required to investigate the vascular 
morphological changes that take place as a result of tyrosine kinase inhibition. It is possible that 
there is an increase in pericyte coverage of these vessels, which would imply improved support and 
resistance against CA-4-P treatment. At the time points studied, there was no difference between 
the treatment groups of VEGF188 tumours and their response to CA-4-P. Further analysis of the 
overall time course and vascular morphological studies would inform on the mechanisms by which 
the reported functional changes in tumour vasculature and response to CA-4-P were brought about. 
 
Analysis of RBC velocities in tumours, using the novel algorithm described, is a useful tool in 
measuring functional responses to vascular-targeted treatments. The number of cells tracked with 
the algorithm vastly exceeds those that could be tracked manually and therefore the measurements 
extracted are statistically more reliable. Further analytical developments to interrogate the 3D tracks 
identified by the algorithm could provide a wealth of further information describing the movement 
of the RBC through the vasculature such as orientation, length of tracks or geometry of functional 
vessels. 
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In summary, by using a functional vascular end-point, namely RBC velocity, this study shows that 
vascular normalization following anti-angiogenic treatment with a VEGF-R tyrosine kinase 
inhibitor can have unexpected consequences for subsequent treatment outcome.  
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Figure Captions 
 
 
Fig 1 Tracks obtained from a video sequence. (a) A single frame showing the intensity of the RBCs 
and 8 tracks detected at this frame. (b) All the tracks detected in the video as a 3D plot with time as 
the z-axis. Colour of the tracks denotes the velocity. (c) A single frame with many detected RBCs 
(white blobs circled in red) with their corresponding coloured tracks. 
 
Fig 2 Transmitted light images of VEGF120 and VEGF188 tumours following treatment with 
SU5416 or drug vehicle. See text for details. Note the reduction in vascularisation in the SU5416-
treated tumours. 
 
Fig. 3 Quantitative analysis of RBC velocities of tumours grown in the dorsal skin-flap window 
chamber. Independent t-test indicates a significant effect of CA-4-P in VEGF120 tumours at 24 
hours after treatment compared with control (time 0), when there was no SU5416 pre-treatment but 
no effect of CA-4-P if VEGF120 tumours were pre-treated with the tyrosine kinase receptor 
inhibitor SU5416 (a). No significant effect of CA-4-P was detected in VEGF188 tumours, at 24 
hours after treatment, regardless of whether tumours were pre-treated with SU5416 (b). * represents 
significance at P < 0.05 between 0 and 24 hrs. 
 
